Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2020-04-15
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the safety and tolerability of
I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone,
in patients with relapsed or refractory multiple myeloma who have previously been treated
with, or are intolerant of, an immunomodulator and a proteasome inhibitor.